Cognitive performance with sirtuin activators

• US 9,241,916 B2
• Filed: 12/13/2007
• Issued: 01/26/2016
• Est. Priority Date: 06/14/2005
• Status: Active Grant

• Current Assignee: President and Fellows of Harvard College (Harvard Corporation)
• Original Assignee: President and Fellows of Harvard College (Harvard Corporation)
• Inventors: Sinclair, David A., Tsai, Li-Huei, Fischer, Andre
• Primary Examiner(s): Chernyshev, Olga N
• Application Number:
  US11/955,680
• Publication Number:
  US 20080194803A1
• Time in Patent Office: 2,966 Days
• Field of Search: None
• US Class Current: 1/1
• CPC Class Codes: A61K 31/015 carbocyclic
• CPC Class Codes: A61K 31/05 Phenols cannabinoids A61K31/658
• CPC Class Codes: A61K 31/122 having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• CPC Class Codes: A61K 31/352 condensed with carbocyclic rings, e.g. methantheline cannabinoids A61K31/658
• CPC Class Codes: A61K 31/415 1,2-Diazoles
• CPC Class Codes: A61K 31/473 ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
• CPC Class Codes: A61K 31/519 ortho- or peri-condensed with heterocyclic rings
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: G01N 2333/98 acting on amide bonds in linear amides (3.5.1)
• CPC Class Codes: G01N 2800/2814 Dementia; Cognitive disorders

Abstract

Provided herein are methods and compositions for enhancing the cognitive performance of a subject in need thereof. A method may include administering to a subject an agent that increases the level of protein or activity of a sirtuin, such as SIRT1.

Claims

1. A method for improving cognitive performance in a mammalian subject, comprising

(i) determining the cognitive performance of a mammalian subject;

(ii) comparing the cognitive performance of the mammalian subject to a control value; and

(iii) administering to the mammalian subject a SIRT1-activating agent if the cognitive performance of the mammalian subject is lower than the control value, wherein the SIRT1-activating agent is a non-naturally occurring compound, and wherein the SIRT1-activating agent is not a stilbene, flavone or flavonoid.

2. The method of claim 1, wherein the control value is a value that corresponds to the usual cognitive performance of the mammalian subject or is a value of the average cognitive performance of a group of control mammalian subjects of similar age to that of the mammalian subject.

3. The method of claim 1, wherein the SIRT1-activating agent is administered orally.

4. The method of claim 1, further comprising administering to the mammalian subject another agent.

5. The method of claim 4, wherein the other agent is an anti-oxidant.

6. The method of claim 1, wherein the mammalian subject is a human.